December 2022 FDA Recall Drug by Remedyrepack Inc.
D-0077-2023 - Subpotent Drug
This Class II drug recall was voluntarily initiated by Remedyrepack Inc. on December 5, 2022 for the product Drug. The FDA reported the reason for recall as subpotent drug. The product was distributed in Product was distributed to two different customers in MI. and the recall is currently terminated.
Recall Number: D-0077-2023
Subpotent Drug: repackaged product was recalled by the manufacturer for subpotency.
12-05-2022
12-14-2022
9 boxes
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
RemedyRepack Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Product was distributed to two different customers in MI.
02-03-2023
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Desmopressin Acetate Tablet, 0.2 mg, 100-count box, Rx only, Source NDC: 23155-0490-01; MFG: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816; Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC #: 70518-3493-00.
Batch or Lot Expiration Information
Lot# B1817019-082222, Exp. 02/24/2023; B1819127-082322, Exp. 02/26/2023